Cytokinetics' MYCorzo: A Game-Changer in HCM Treatment

Cytokinetics MYCorzo makes a fiery debut, exceeding expectations with $4.8M in Q1 revenue and positive HCM trial results. European approval paves the way for German launch. Strong doctor and patient response, with 80% of key heart specialists aware and high-volume HCM docs favoring the drug. Sales team reaches 90% of top prescribers, signaling real differentiation in a competitive market. Acacia data shows improved quality of life and exercise capacity. FDA talks planned for full HCM spectrum coverage, with MAPLE HCM filing accepted and ongoing trials in kids, Japan, and heart failure. Cash balance at $1.1B, poised for global growth and pipeline advancement. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/77785f44c9321773